| Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
|
MELLIN GW, 1962, NEW ENGL J MED, V267, P1184 MELLIN GW, 1962, NEW ENGL J MED, V267, P1238 LENZ W, 1961, DEUT MED WOCHENSCHR, V86, P2555 LENZ W, 1962, DEUT MED WOCHENSCHR, V87, P1232 KUNZ W, 1956, ARZNEIMITTEL-FORSCH, V6, P426 SHESKIN J, 1965, LEPROSY REV, V36, P183 WIEDEMANN HR, 1961, MED WELT, V37, P1863 BECKMANN R, 1962, ARZNEIMITTEL-FORSCH, V12, P1095 |
Nodes: 2685,
Authors: 6203,
Journals: 662,
Outer References: 16023,
Words: 3995
Collection span: 1956 - 2004
View: Overview. Sorted by journal name.
Page 3: 1 2 3 4 5 6 7 8 9
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
|---|---|---|---|---|---|
| 601 | 0 | 0 | 2070 2002 BLOOD 100(11):170A-170A Neben K; Mytilineos J; Kraemer A; Moehler TM; Preiss A; Ho AD; Opelz G; Goldschmidt H Thalidomide is able to improve the outcome in patients carrying the high producer haplotype of the interleukin-10 gene promoter in multiple myeloma. | 0 | 0 |
| 602 | 0 | 0 | 2071 2002 BLOOD 100(11):178A-178A Brinker B; Waller EK; Langston AA; Redei I; Smith KJ; Bucur SZ; Winton E; Lyles R; Heffner LT; Lonial S Therapy with thalidomide enhances overall survival after autologous PBSC transplant for multiple myeloma. | 0 | 0 |
| 603 | 0 | 0 | 2072 2002 BLOOD 100(11):209A-209A Weber D; Ginsberg C; Walker P; Obolendt M; Rankin K; Gavino M; Delasalle K; Alexanian R Correlation of thrombotic/embolic events (T/E) with features of hypercoagulability in previously untreated patients before and after treatment with thalidomide (T) or thalidomide-dexamethasone (TD). | 0 | 2 |
| 604 | 0 | 0 | 2073 2002 BLOOD 100(11):210A-210A Barlogie B; Tricot G; Anaissie E; Fassas A; Lee CK; Thertulien R; van Rhee F; Zangari M Long-term follow-up (median of 4 yr) of 169 patients receiving thalidomide (THAL) for advanced and refractory multiple myeloma (MM): Superior survival in the absence of cytogenetic abnormalities (CA) and low beta-2 microglobulin (B2M). | 0 | 0 |
| 605 | 0 | 0 | 2074 2002 BLOOD 100(11):211A-211A Palumbo A; Bertola A; Cavallo F; Falco P; Bringhen S; Giaccone L; Musto P; Pregno P; Boccadoro M Low-dose thalidomide and dexamethasone improves survival in advanced multiple myeloma. | 0 | 3 |
| 606 | 0 | 0 | 2075 2002 BLOOD 100(11):211A-211A Myers B; Jones SG; McMillan AK; Dolan G Zoledronic acid, hypocalcaemia and renal dysfunction in thalidomide-treated myeloma patients. | 0 | 0 |
| 607 | 0 | 0 | 2076 2002 BLOOD 100(11):265B-265B Manson SD; Gregory SA; Rogers K; Raza A; Loew J; Hsu WT; Sivaraman S; Venugopal P Thalidomide as a single agent leads to meaningful responses in older patients with poor prognosis acute myeloid leukemia (PP-AML) | 0 | 0 |
| 608 | 0 | 0 | 2077 2002 BLOOD 100(11):314B-314B Hayashi T; Anderson KC; Steven SP Rituximab induced antibody dependent cell mediated cytotoxicity (ADCC) is enhanced by thalidomide and its analogue revimid. | 0 | 1 |
| 609 | 0 | 0 | 2078 2002 BLOOD 100(11):336B-336B Musto P; Falcone A; Sanpaolo G; Bodenizza C; Bisceglia M; Matera R; Minervini MM; Carella AM Does thalidomide act with different mechanisms of action in myelodysplastic syndromes? | 0 | 0 |
| 610 | 0 | 0 | 2079 2002 BLOOD 100(11):337B-337B Shetty V; Alvi S; Zorat F; Patkar S; Zahid S; Khan T; Mundle S; Galili N; Reddy P; Alvi M; Lisak L; Gezer S Effect of the anti-angiogenic agent thalidomide on the biological characteristics of patients with myelodysplastic syndromes. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 611 | 0 | 0 | 2080 2002 BLOOD 100(11):340B-340B Raza A; Lisak LA; Tahir S; Billmeier JM; Willmann HS; Alvi MI; Bellak DJ; Gezer S; Venugopal P Combination of thalidomide and etanercept (Tumor necrosis factor receptor OR TNFR) effective in improving the cytopenias of some patients with myelodysplastic syndromes (MDS). | 0 | 2 |
| 612 | 0 | 0 | 2081 2002 BLOOD 100(11):341B-341B Islam A; Bielat K; Smith G Does thalidomide have an effect other than anti-angiogenesis. | 0 | 0 |
| 613 | 0 | 0 | 2082 2002 BLOOD 100(11):346B-346B Grossi A; Gavazzi S; Biscardi M; Balestri F; Bonsi L; Bagnara G; Pierdomenico L; Mazzucconi F Thalidomide therapy effects on angiogenic growth factors (VEGF, TGF-beta) and KDR expression in myeloid metaplasia with myelofibrosis. | 0 | 1 |
| 614 | 0 | 0 | 2083 2002 BLOOD 100(11):367B-367B Luo SK; Li J; Hong WD; Zhou ZH Immunoreactivity of thalidomide in patients with multiple myeloma. | 0 | 0 |
| 615 | 0 | 0 | 2084 2002 BLOOD 100(11):371B-371B Payvandi F; Wu L; Zhang LH; Muller G; Chen R; Stengel J; Harriri R; Stirling D Thalidomide and IMiDs inhibit microvessel formation from human arterial rings in the absence of human liver microsomes. | 0 | 0 |
| 616 | 0 | 0 | 2085 2002 BLOOD 100(11):375A-375A Alvi S; Borok RZ; Shaher A; Anthwal S; Shaikh M; Alvi I; Tahir S; John P; Shetty V; Galili N; Raza A Thalidomide significantly modifies bone marrow microenvironment in myelodysplastic syndrome (MDS) patients. | 0 | 0 |
| 617 | 0 | 0 | 2086 2002 BLOOD 100(11):377B-377B Lincz LF; Enno A Thalidomide induced alterations in multiple myeloma cell surface receptor expression do not affect adhesion to bone marrow stroma or correlate with VEGF secretion in vitro. | 0 | 0 |
| 618 | 0 | 0 | 2087 2002 BLOOD 100(11):380B-380B Waage A; Romstad L; Brenne AT; Gimsing P; Juliusson G; Turesson I; Borset M; Sundan A Low serum levels of soluble tumor necrosis factor receptors predict for response to thalidomide in advanced myeloma. | 0 | 1 |
| 619 | 0 | 0 | 2088 2002 BLOOD 100(11):384B-384B Devabhaktuni YD; Laber DA Secondary plasma cell leukemia associated with thalidomide in a patient with multiple myeloma. | 0 | 0 |
| 620 | 0 | 0 | 2089 2002 BLOOD 100(11):384B-384B Dimopoulos MA; Tsatalas C; Zomas A; Hamilos G; Panayiotidis P; Anagnostopoulos N; Gika D; Margaritis D; Economopoulos T Clarithromycin, thalidomide and dexamethasone for the treatment of Waldenstrom's macroglobulinemia. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 621 | 0 | 0 | 2090 2002 BLOOD 100(11):384B-384B Fawaz A; Magro L; Leleu X; Depil S; Guillerm G; Corm S; Bauters F; Facon T; Yakoub-Agha I Impact of thalidomide on survival of patients with multiple myeloma. | 0 | 2 |
| 622 | 0 | 0 | 2091 2002 BLOOD 100(11):385B-385B Caravita T; Arciprete F; Siniscalchi A; Santinelli S; Iani C; Amadori S Thalidomide induced neuropathy in patients treated for multiple myeloma. | 0 | 0 |
| 623 | 0 | 0 | 2092 2002 BLOOD 100(11):387B-387B Helgason HH; Smit WM; de Groot MR; Schenkeveld CEI; Neef C; Schaafsma MR Long term survival and complete remission of chemotherapy refractory multiple myeloma with thalidomide. | 0 | 0 |
| 624 | 0 | 0 | 2093 2002 BLOOD 100(11):387B-387B Dmoszynska A; Manko J; Jawniak D; Ciepluch H; Hellmann A; Wolska-Smolen T; Skotnicki A; Soroka-Wojtaszko M; Urbanska-Rys H; Konopka L; Hus M Toxicity of thalidomide in multiple myeloma patients (long-term observations). | 0 | 0 |
| 625 | 0 | 0 | 2094 2002 BLOOD 100(11):387B-387B Meng HT; Jin J; Mai WY Thalidomide plus M2 chemotherapy in the treatment of refractory multiple myeloma. | 0 | 0 |
| 626 | 0 | 0 | 2095 2002 BLOOD 100(11):388B-388B Musto P; Falcone A; Sanpaolo G; La Sala A; Mantuano S; Cascavilla N; Melillo L; Dell'Olio M; Nobile M; Bodenizza C; Carella AM A combined therapy with thalidomide, dexamethasone and zoledronate is highly effective and well tolerated in pre-treated patients with multiple myeloma. | 0 | 1 |
| 627 | 0 | 0 | 2096 2002 BLOOD 100(11):389B-389B Keyzner A; Kumar A; Besa EC The role of thalidomide and pamidronate in maintenance of plateau phase after second and third induction therapy in relapsed multiple myeloma patients. | 0 | 0 |
| 628 | 0 | 0 | 2097 2002 BLOOD 100(11):389B-389B Huang JW; Wang YH; Du HP; Zhang J Thalidomide combined with conventional melphalan and predisone regimen for treatment of mulitiple myeloma | 0 | 0 |
| 629 | 0 | 0 | 2098 2002 BLOOD 100(11):390B-390B Sidra GM; Russell N; Byrne J; Myers B; Mitchell D Combination therapy with thalidomide, cyclophosphamide and dexamethasone (C-ThaD) for VAD-refractory and relapsed myeloma. | 0 | 0 |
| 630 | 0 | 0 | 2099 2002 BLOOD 100(11):390B-390B Alegre A; Gil-Fernandez JJ; Font P; Alonso A; Sureda A; Martinez-Chamorro C; Escudero A; Sanchez-Godoy P; Burgaleta C; Casado LF; Granda A; Aguado B; Osorio S; Nistal S; Mascunano R; Prieto E; Fernandez-Ranada JM Thalidomide as rescue of relapses after haematopoietic transplantation in multiple myeloma and as maintenance treatment: Results of a Spanish multicentre study including 63 patients. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 631 | 0 | 0 | 2100 2002 BLOOD 100(11):390B-390B Breitkreutz I; Cremer FW; Benner A; Raab MS; Moehler T; Egerer G; Christensen O; Herrmann D; Ho AD; Goldschmidt H Peripheral blood stem cell collection (PBSC) after CAD plus G-CSF in multiple myeloma: No influence of previous thalidomide (Thai) administration. | 0 | 0 |
| 632 | 0 | 0 | 2101 2002 BLOOD 100(11):390B-390B Sato N; Kakimoto T; Hattori Y; Okamoto S; Morita K; Tanigawara Y; Ikeda Y Thalidomide induced severe neutropenia during the treatment of multiple myeloma via direct suppression of bone marrow hematopoiesis. | 0 | 0 |
| 633 | 0 | 0 | 2102 2002 BLOOD 100(11):392B-392B Kazmi MA; Cuadrado MJ; Karim MY; Jones RJ; Khamashta MA; Schey SA Comparison of thalidomide toxicity profiles in treatment of Lupus and myeloma: Efficacy and toxicity are not dose dependent. | 0 | 0 |
| 634 | 0 | 0 | 2103 2002 BLOOD 100(11):393B-393B Moehler TM; Schlenzka J; Kasper B; Neben K; Egerer G; Ho AD; Goldschmidt H Low incidence of deep venous thrombosis in poor prognosis multiple myeloma patients treated with thalidomide and CED chemotherapy. | 0 | 0 |
| 635 | 0 | 0 | 2104 2002 BLOOD 100(11):393A-393A Bahlis NJ; Sawney R; Gerson S PKC delta inhibition induces cell death in thalidomide and dexamethasone resistant multiple myeloma cell lines. | 0 | 0 |
| 636 | 0 | 0 | 2105 2002 BLOOD 100(11):394A-395A Minnema MM; Fijnheer R; De Groot PG; Lokhorst HM Factor VIII procoagulant activity as risk factor for deep venous thrombosis in patients with Multiple Myeloma during treatment with thalidomide. | 0 | 0 |
| 637 | 0 | 0 | 2106 2002 BLOOD 100(11):397A-397A Palladini G; Perfetti V; Obici L; Merlini G Thalidomide toxicity in patients with AL (primary) amyloidosis. | 0 | 3 |
| 638 | 0 | 0 | 2107 2002 BLOOD 100(11):398A-398A Zangari M; Barlogie B; Anaissie FJ; Saghafifar F; Fassas A; Lee CK; Thertulien R; van Rhee F; Zeldis J; Fink L; Tricot G Abrogation of thrombogenic effect of the doxorubicin (DOX)- thalidomide (THAL) combination as part of total therapy II (TTII) for newley diagnosed multiple myeloma (MM) by effective anti-coagulation with low molecular weight heparin (LMWH). | 0 | 2 |
| 639 | 0 | 0 | 2108 2002 BLOOD 100(11):398A-398A Dispenzieri A; Lacy MQ; Rajkumar SV; Geyer SM; Fonseca R; Witzig TE; Lust JA; Greipp PR; Kyle RA; Gertz MA High doses of thalidomide are not well tolerated in patients with primary systemic amyloidosis. | 0 | 2 |
| 640 | 0 | 0 | 2109 2002 BLOOD 100(11):401A-402A Prince M; Mileshkin L; Biagi JJ; Smith JG; Mitchell P; Underhill C; Grigg A; Bell R; McKendrick J; Briggs P; Seymour JF; Simmons PJ; Zeldis JB A multicentre phase-II trial of thalidomide in relapsed/refractory multiple myeloma (MM) reveals a dominant adverse prognostic impact of advanced age. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 641 | 0 | 0 | 2110 2002 BLOOD 100(11):402A-402A Oakervee HE; McBride NC; Hemmaway CJ; Brownell A; Cervi P; Crawley C; Gale R; Grant I; Hamblin M; Lewis D; Rahemtulla A; Barnett MJ; Cavenagh JD Thalidomide combined with vincristine, adriamycin and dexamethasone (T-VAD) is effective treatment for multiple myeloma and does not prejudice successful stem cell harvesting. | 0 | 2 |
| 642 | 0 | 0 | 2111 2002 BLOOD 100(11):402A-403A Kropff MH; Lang N; Bisping G; Domine N; Schneider P; Suedhoff T; Innig G; Straka C; Ostermann H; Berdel WE; Kienast J Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in advanced multiple myeloma: Final results of a phase II trial. | 0 | 1 |
| 643 | 0 | 0 | 2112 2002 BLOOD 100(11):403A-403A Hussein MA; Elson P; Tsoe EA; Karam M; Srkaloci G Doxil (D), vincristine (V), decadron (D) and thalidomide (T) (DVd-T) for relapsed/refractory multiple myeloma (RMM). | 0 | 4 |
| 644 | 0 | 0 | 2113 2002 BLOOD 100(11):403A-404A Rajkumar SV; Gertz MA; Lacy MQ; Dispenzieri A; Fonseca R; Geyer S; Iturria N; Kumar S; Lust JA; Kyle RA; Greipp PR; Witzig TE Single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma. | 0 | 0 |
| 645 | 0 | 0 | 2114 2002 BLOOD 100(11):426B-426B Santos E; Goodman M; Byrnes JJ; Fernandez HF Thalidomide as maintenance therapy in the post-transplantation setting in patients with multiple myeloma. | 0 | 0 |
| 646 | 0 | 0 | 2115 2002 BLOOD 100(11):434A-434A Ghobrial IM; Kumar S; Porrata LF; Gertz MA; Gastineau DA; Ansell SM; Lacy MQ; Rajkumar VS; Micallef IN; Tefferi A; Dispenzieri A; Inwards D; Litzow MR; Markovic SN Thalidomide does not affect immune reconstitution post-autologous bone marrow transplantation in Multiple Myeloma. | 0 | 0 |
| 647 | 0 | 0 | 2116 2002 BLOOD 100(11):477B-477B Cottler-Fox M; Barlogie B; Anaissie E; Zangari M; Fassas A; Lee CK; van Rhee F; Thertulien R; Tricot G Determinants of high and low CD 34 yield after CAD as part of Total Therapy II (TT II) for newly diagnosed Multiple Myeloma (MM): Effect of Thalidomide (THAL). | 0 | 0 |
| 648 | 0 | 0 | 2117 2002 BLOOD 100(11):671A-671A LeBlanc R; Hideshima T; Hayashi T; Catley LP; Burger R; Shringarpure R; Cheema P; Richardson P; Anderson KC; Munshi NC Thalidomide analogue IMiD3 provides T cell co-stimulation through B7-CD28 pathway. | 0 | 0 |
| 649 | 0 | 0 | 2118 2002 BLOOD 100(11):795A-795A Raza A; Lisak LA; Tahir S; Billmeier JM; Willmann HS; Alvi MI; Patkar S; Khan T; Rizvi A; Venugopal P; Gezer S; Mundle SD; Reddy PL Trilineage responses to arsenic trioxide (Trisenox (R)) and thalidomide in patients with myelodysplastic syndromes (MDS), particularly those with inv(3)(q21q26.2). | 0 | 0 |
| 650 | 0 | 0 | 2119 2002 BLOOD 100(11):800A-800A Barosi G; Elliott M; Canepa L; Ballerini F; Piccaluga PP; Visani G; Marchetti M; Pozzato G; Zorat F; Tefferi A Thalidomide in Myelofibrosis with Myeloid Metaplasia: A pooled-analysis of individual patient data from five studies. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 651 | 0 | 0 | 2120 2002 BLOOD 100(11):808A-809A Weber D; Albitar M; Delasalle K; Dey A; Rankin K; Gavino M; Walker P; Alexanian R Correlation of peripheral blood plasma levels of angiogenesis factors with treatment of thalidomide (T) or thalidomide-dexamethasone (TD) in prevoiusly untreated patients with multiple myeloma (MM). | 0 | 1 |
| 652 | 0 | 0 | 2121 2002 BLOOD 100(11):811A-811A Thompson MA; Witzig TE; Timm MM; Haug J; Kumar S; Fonseca R; Greipp PR; Rajkumar SV Angiogenesis and angiogenic cytokines in patients receiving thalidomide for multiple myeloma (MM). | 0 | 1 |
| 653 | 0 | 0 | 2122 2002 BLOOD 100(11):813A-813A Richardson P; Jagannath S; Schlossman R; Alsina M; Desikan RK; Blood E; Weller E; Mitsiades C; Hideshima T; Davies F; Doss D; Freeman A; Bosch J; Patin J; Dalton W; Anderson KC Thalidomide for relapsed multiple myeloma after high dose therapy and stem cell transplantation: Results of an open-label, multicenter phase two study of efficacy, toxicity and correlation with biological activity. | 0 | 0 |
| 654 | 0 | 0 | 2123 2002 BLOOD 100(11):815A-815A Hayashi T; Hideshima T; Akiyama M; Munshi N; Chauhan D; Anderson KC Mechanisms whereby immunomedulatory analogs of thalidomide augment autologous NK cell anti-myeloma immunity. | 0 | 1 |
| 655 | 0 | 0 | 2124 2002 BLOOD 100(11):816A-816A Treston AM; Swartz GM; Conner B; Shah J; Pribluda VS Pre-clinical evaluation of a thalidomide analog with activity against multiple myeloma and solid tumors - ENMD-0995 (S-(-)3- (3-amino-phthalimido)-glutarimide). | 0 | 1 |
| 656 | 26 | 39 | 2125 2002 BLOOD 100(12):4162-4168 Yaccoby S; Johnson CL; Mahaffey SC; Wezeman MJ; Barlogie B; Epstein J Antimyeloma efficacy of thalidomide in the SCID-hu model | 1 | 6 |
| 657 | 15 | 47 | 2338 2003 BLOOD 101(7):2534-2541 Mesa RA; Steensma DP; Pardanani A; Li CY; Elliott M; Kaufmann SH; Wiseman G; Gray LA; Schroeder GE; Reeder T; Zeldis JB; Tefferi A A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia | 5 | 8 |
| 658 | 0 | 4 | 2339 2003 BLOOD 102(1):2-3 Hussein MA Thalidomide, age, and future use in multiple myeloma | 0 | 0 |
| 659 | 18 | 42 | 2340 2003 BLOOD 102(1):69-77 Mileshkin L; Biagi JJ; Mitchell P; Underhill C; Grigg A; Bell R; McKendrick J; Briggs P; Seymour JF; Lillie K; Smith JG; Zeldis JB; Prince HM Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age | 7 | 10 |
| 660 | 0 | 0 | 2341 2003 BLOOD 102(11):33A-33A Mesa RA; Elliott MA; Faoro L; Tefferi A Durable and unmaintained remissions with thalidomide-based drug therapy in myelofibrosis with myeloid metaplasia: Long term outcome analysis of 2 prospective trials. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 661 | 0 | 0 | 2342 2003 BLOOD 102(11):56B-56B Ballester G; Ballester O; Daitch L; Kutlar A Response to thalidomide therapy in multicentric Castleman's disease. | 0 | 0 |
| 662 | 0 | 0 | 2343 2003 BLOOD 102(11):148A-148A Palumbo A; Bertola A; Musto P; Nunzi M; De Stefano V; Callea V; Rotoli B; Petti MC; Caravita T; Lauta VM; Patti C; Bringhen S; Cavallo F; Falco P; Carella AM; Liberati AM; Boccadoro M Oral melphalan, prednisone and thalidomide for newly diagnosed myeloma. | 0 | 0 |
| 663 | 0 | 0 | 2344 2003 BLOOD 102(11):148A-149A Dimopoulos MA; Anagnostopoulos A; Hamilos G; Zomas A; Efstathiou E; Grigoraki V; Poziopoulos C; Gika D; Xilouri I; Zorzou MP; Anagnostopoulos N Pulsed cyclophosphamide, thalidomide and dexamethasone: Long term follow-up of an oral regimen for previously treated patients with multiple myeloma. | 0 | 0 |
| 664 | 0 | 0 | 2345 2003 BLOOD 102(11):149B-149B Moutouh-de Parseval LA; Glezer E; Corral L; Muller G; Brady H; Mercurio F; Chan K Immunomodulatory thalidomide analogs modulate hematopoietic stem cells developmental pathway. | 0 | 0 |
| 665 | 0 | 0 | 2346 2003 BLOOD 102(11):236A-236A Zangari M; Barlogie B; Jacobson J; Rasmussen E; Burns M; Kordsmeier B; Shaughnessy JD; Anaissie EJ; Thertulien R; Fassas A; Lee CK; Schenkein D; Zeldis JB; Tricot G VTD regimen comprising velcade (V) plus thalidomide (T) and added DEX (D) for non-responders to V+T effects a 57% PR rate among 56 patients with myeloma (M) relapsing after autologous transplant. | 0 | 3 |
| 666 | 0 | 0 | 2347 2003 BLOOD 102(11):237A-237A Agrawal NR; Hussein MA; Elson P; Karam MA; Reed J; Srkalovic G Pegylated Doxorubicin(D), Vineristine(V), reduced frequency Dexamethasone(D) and Thalidomide(T) (DVd-T) in newly diagnosed (Nmm) and relapsed/refractory (Rmm) multiple myeloma patients. | 0 | 0 |
| 667 | 0 | 0 | 2348 2003 BLOOD 102(11):237A-237A Niesvizky R; Pekle K; Lyons L; Pearse RN; Bergsagel PL; Schuster MW; Cho HJ; Leonard JP; Coleman M Dexamethsone alone, or in combination with low-dose thalidomide as induction therapy for advanced multiple myeloma, and the effect of the addition of clarithromycin (Biaxin(TM)) on response rate. interim results of a prospective, sequential, randomized trial. | 0 | 0 |
| 668 | 0 | 0 | 2349 2003 BLOOD 102(11):259B-259B Cooper BW; Koc ON; Lazarus HM; Laughlin MJ; Myerson HJ; Creger RJ Phase II study of fludarabine, carboplatin, topotecan, and thalidomide for patients with acute myelogenous leukemia and advanced myelodysplastic syndromes. | 0 | 0 |
| 669 | 0 | 0 | 2350 2003 BLOOD 102(11):327B-328B Musto P; Falcone A; Sanpaolo G; Bodenizza C; La Sala A; Carella AM Once-weekly recombinant erythropoietin plus thalidomide for the anemia of low-to-intermediate risk myelodysplastic syndromes. | 0 | 0 |
| 670 | 0 | 0 | 2351 2003 BLOOD 102(11):330B-330B Leb LV; Becker P; Brettler D; Church AA; Khanani SA; Rooney JJ; Seidler CW; Yang J; Woda B The potentiating effect of low dose thalidomide given in combination with epoetin alfa in patients with myelodysplastic syndrome (MDS) having low International Prognostic Scoring Systems (IPSS). | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 671 | 0 | 0 | 2352 2003 BLOOD 102(11):353B-353B Chanan-Khan AA; Stein L; David S; Takeshita K; Platt J; Miller K; Fallon A; Czuczman MS; Hawthorn L Thalidomide (T) induced in vivo changes in gene expression profile (GEP) of malignant chronic lymphocytic leukemia (CLL) cells. | 0 | 0 |
| 672 | 0 | 0 | 2353 2003 BLOOD 102(11):359B-359B Kay N; Geyer S; Yaqoob I; Phyliky R; Kutteh L; Li CY Thalidomide (Td) treatment in chronic lymphocytic leukemia (CLL): A North Central Cancer Treatment Group (NCCTG) study. | 0 | 0 |
| 673 | 0 | 0 | 2354 2003 BLOOD 102(11):366B-367B Okikawa Y; Sakai A; Kuroda Y; Katayama Y; Takimoto Y; Okita H; Kimura A Analysis of the maturity of myeloma cells (plasma cells) is useful to select effective chemotherapy including thalidomide and to predict the progressive disease. | 0 | 0 |
| 674 | 0 | 0 | 2355 2003 BLOOD 102(11):378B-378B Agrawal NR; Srkalovic G; Sup S; Hsi ED; Elson P; Hussein MA Impact of pegylated doxorubicin(D), vincristine(V), reduced frequency dexamethasone(D) and thalidomide(T) {DVd-T} on bone marrow microvessel density (MVD) in newly diagnosed multiple myeloma (MM) patients (pts). | 0 | 0 |
| 675 | 0 | 0 | 2356 2003 BLOOD 102(11):380B-380B Myers B; Russell NH; McMillan AK Use of a novel combination chemotherapy for AL-amyloidosis: Cyclophosphamide, thalidomide and dexamethasone - Serum free light chain (SFLC) and serum amyloid protein P (SAP) scan results. | 0 | 0 |
| 676 | 0 | 0 | 2357 2003 BLOOD 102(11):381B-381B Breitkreutz I; Cremer FW; Benner A; Moehler T; Fruehauf S; Herrmann D; Ho AD; Goldschmidt H Peripheral blood stem cell collection after CAD plus G-CSF in multiple myeloma: No influence of previous thalidomide administration. | 0 | 0 |
| 677 | 0 | 0 | 2358 2003 BLOOD 102(11):381B-381B Offidani M; Marconi M; Corvatta L; Malerba L; Olivieri A; Barulli S; Capelli D; Rupoli S; Leoni P Combination therapy with Caelyx, dexamethasone and thalidomide (CDT) for multiple myeloma (MM): Preliminary results of a phase II-III study. | 0 | 0 |
| 678 | 0 | 0 | 2359 2003 BLOOD 102(11):382B-382B Musto P; Bodenizza C; Falcone A; Sanpaolo G; Cascavilla N; Melillo L; Dell'Olio M; La Sala A; Mantuano S; Nobile M; Scalzulli PR; Greco MM; Carella AM; Beltrami G; Carella AM Treatment of myeloma patients relapsed after frontline autologous stem cell transplantation with the association of thalidomide, dexamethasone and zoledronate. | 0 | 1 |
| 679 | 0 | 0 | 2360 2003 BLOOD 102(11):382B-382B Novoselac AV; Reddy S; Ohsumi F; Sherman RE; Samaha S Acute myeloid leukemia in patient with multiple myeloma treated with thalidomide. | 0 | 0 |
| 680 | 0 | 0 | 2361 2003 BLOOD 102(11):382B-383B Caravita T; Siniscalchi A; Niscola P; Santinelli S; Buccisano F; Montanaro M; De Fabritiis P; Amadori S Low dose thalidomide in combination with dexamethasone and cyclophosphamide for management of relapsed/refractory multiple myeloma. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 681 | 0 | 0 | 2362 2003 BLOOD 102(11):383B-383B Guglielmelli T; Capella S; Mattioli G; Guerrasio A; Saglio G Thalidomide at very low dosage may represent an effective therapy in relapsed and refractory multiple myeloma. | 0 | 0 |
| 682 | 0 | 0 | 2363 2003 BLOOD 102(11):383B-384B Spencer A; Roberts A; Bailey M; Schran H; Lynch K No evidence for an adverse interaction between zoledronic acid and thalidomide: Preliminary safety analysis from the Australasian Leukaemia and Lymphoma Group (ALLG) MM6 myeloma trial. | 0 | 0 |
| 683 | 0 | 0 | 2364 2003 BLOOD 102(11):385B-385B Di Raimondo F; Pennisi A; Buglio D; Fiumara P; Palumbo GA; Giustolisi R Addition of low dose Cyclophosphamide to the combination of Thalidomide and Dexamethasone in patients with relapsed/refractory multiple myeloma. | 0 | 0 |
| 684 | 0 | 0 | 2365 2003 BLOOD 102(11):385B-386B Tosi P; Zamagni E; Cellini C; Cangini D; Tacchetti P; Tura S; Baccarani M; Cavo M Combined thalidomide-dexametasone and zoledronic acid induce a reduction of bone resorption markers in newly diagnosed multiple myeloma patients. | 0 | 0 |
| 685 | 0 | 0 | 2366 2003 BLOOD 102(11):386B-386B Kyriakou CA; D'Sa SP; Flory A; Hanslip J; Peggs KS; Yong KL Cyclophosphamide, dexamethasone and thalidomide (CDT) is a well tolerated and effective regimen in advanced relapsed/refractory myeloma. | 0 | 0 |
| 686 | 0 | 0 | 2367 2003 BLOOD 102(11):387B-387B Kumar S; Witzig TE; Wellik L; Fonseca R; Dispenzieri A; Lacy MQ; Lust JA; Kyle RA; Gertz MA; Greipp PR; Rajkumar SV Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. | 0 | 0 |
| 687 | 0 | 0 | 2368 2003 BLOOD 102(11):389B-389B Chanan-Khan AA; Miller K; Srinivasan S; David S; McCarthy P; Alam A; Bernstein ZP; Czuczman MS Velcade (Vel), Doxil (R) (Dox) and low-dose thalidomide (Thal) as salvage therapy for patients (pts) with relapsed/refractory multiple myeloma (MM). | 0 | 0 |
| 688 | 0 | 0 | 2369 2003 BLOOD 102(11):390B-390B Oyan B; Koc Y; Kars A; Turker A; Tekuzman G; Kansu E Achieving high remission rate with use of autologous HSCT, thalidomide maintenance and non-myeloablative allogeneic HSCT in patients with multiple myeloma. | 0 | 0 |
| 689 | 0 | 0 | 2370 2003 BLOOD 102(11):443A-443A El-Sherbiny YM; Davies FE; Cook G; Johnson RJ; Cullen MJ; Sah A; Rawstron AC; Richards SJ; Morgan GJ NK cell repertoire in myeloma and the impact of thalidomide. | 0 | 0 |
| 690 | 0 | 0 | 2371 2003 BLOOD 102(11):448A-448A Cavo M; Zamagni E; Tosi P; Cellini C; de Vivo A; Cangini D; Tonelli M; Testoni N; Grafone T; Tacchetti P; Soverini S; Terragna C; Tura S; Baccarani M Primary therapy with thalidomide and dexamethasone in preparation to autologous transplantation for multiple myeloma. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 691 | 0 | 0 | 2372 2003 BLOOD 102(11):449A-449A Patten PE; Ahsan G; Kazmi M; Fields PA; Chick GW; Jones RR; Bradwell AR; Schey SA The early use of the serum free light chain assay in patients with relapsed refractory myeloma receiving treatment with a thalidomide analogue (CC-4047). | 0 | 0 |
| 692 | 0 | 0 | 2373 2003 BLOOD 102(11):450A-450A Zervas K; Dimopoulos MA; Hatziharisi E; Anagnostopoulos A; Papaioannou M; Mitsouli C; Panagiotidis P; Korantzis L; Tzilianos M; Maniatis A Primary treatment of mutiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): A phase II multicenter study. | 0 | 0 |
| 693 | 0 | 0 | 2374 2003 BLOOD 102(11):450A-451A Comenzo RL; Hassoun H; Reich L; Klimek V; Kewalramani T; Dhodapkar M; Drake L; Hedvat C; Teruya-Feldstein J; Fleisher M; Filippa DA; Nimer SD Doxorubicin and dexamethasone (AD) followed by thalidomide and dexamethasone (TD) as initial therapy for symptomatic patients with multiple myeloma. | 0 | 0 |
| 694 | 0 | 0 | 2375 2003 BLOOD 102(11):453A-453A Lacy MQ; Dispenzieri A; Gertz MA; Wilzig TE; Greipp PR; Fonseca R; Lust JA; Kumar S; Zeldenrust S; Kyle RA; Snow D; Hayman SR; Sidor CF; Treston AM; Zeldis JB; Rajkumar SV ENMD-0995 (S 3-APG), a novel thalidomide analogue, has promising clinical activity for patients with relapsed refractory multiple myeloma. Preliminary results of a phase I clinical trial. | 0 | 1 |
| 695 | 0 | 0 | 2376 2003 BLOOD 102(11):453A-454A Abonour R; Ganjoo K; Fausel C; Yiannoutsos C; Juliar BE; Wood LL; Smith GG; Walker P; Cripe LD A phase II study of oral cyclophosphamide, thalidomide, and prednisone (CTP) for patients with relapsed or refractory multiple myeloma, a Hoosier Oncology Group (HOG) trial: HEM01-21. | 0 | 0 |
| 696 | 0 | 0 | 2377 2003 BLOOD 102(11):454A-454A Anaissie EJ; Jacobson J; Fassas AB; Zangari M; Thertulien R; VanRhee F; Talamo G; Tricot G; Wendling C; Davis CK; Hollmig K; Barlogie B Safety of total therapy II with or without thalidomide (THAL) for newly diagnosed myeloma: A study of 475 consecutive patients. | 0 | 0 |
| 697 | 0 | 0 | 2378 2003 BLOOD 102(11):454A-454A Anagnostopoulos A; Efstathiou E; Hamilos G; Zorzou MP; Kastritis E; Dimopoulos MA Patterns of progression in myeloma patients treated with thalidomide-based regimens: High incidence of extramedullary progression without serologic relapse. | 0 | 0 |
| 698 | 0 | 0 | 2379 2003 BLOOD 102(11):456B-456B Yakoub-agha I; Mohty M; Attal M; Marit G; Bulabois CE; Sotto JJ; Gratecos N; Rio B; Vernant JP; Dib M; Garban F; Cahn JY; Jouet JP; Facon T Thalidomide (THAL) as salvage therapy for relapsed multiple myeloma (MM) after allogeneic stem cell transplantation (SCT). | 0 | 0 |
| 699 | 0 | 0 | 2380 2003 BLOOD 102(11):489B-490B Grosskreutz CL; Egan R; Scigliano E; Fruchtman SM; Isola LM Thalidomide maintenance after autologous stem cell transplantation for multiple myeloma. | 0 | 0 |
| 700 | 0 | 0 | 2381 2003 BLOOD 102(11):490B-490B Castro J; Davila J; Perez S; Flores L; Lopez A; Roman A; Pacheco E; Fernandex A; Fradera J; Garcia R; Merle S; Velez-Garcia E High dose chemotherapy (HDC) with autologous transplant (AT) followed by thalidomide (T) as maintenance in patients (P) with multiple myeloma (MM). | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 701 | 0 | 0 | 2382 2003 BLOOD 102(11):554A-554A Biemond BJ; Havik SR; Meijers JCM; Levi MM; Van Oers MHJ Strong thrombogenic activity of the combined administration of thalidomide and doxorubicin in experimental thrombosis in the rabbit. | 0 | 0 |
| 702 | 0 | 0 | 2383 2003 BLOOD 102(11):675A-675A Chanan-Khan AA; Fallon A; Miller K; Bernstein ZP; Hernandez F; Alam A; McCarthy P; Mohr A; Czuczman MS Thalidomide (T) and fludarabine (F) as front-line therapy for patients (pts) with previously untreated chronic lymphocytic leukemia (CLL): Results of a phase I trial. | 0 | 0 |
| 703 | 0 | 0 | 2384 2003 BLOOD 102(11):684A-684A Badros AZ; Ratterree B; Natt S; Rapoport AP; Zeldis JB; Frankel SR; Meisenberg B; Takebe N; Zwiebel JA; Zhang B; Fenton R Phase I/II trial of oblimersen sodium (G3139), dexamethasone (Dex) and thalidomide (Thal) in patients with relapsed multiple myeloma. | 0 | 0 |
| 704 | 0 | 0 | 2385 2003 BLOOD 102(11):686A-686A Hovenga S; Daenen SMGJ; de Wolf JTM; van Imhoff GW; Kluin-Nelemans HC; Vellenga E Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma. A prospective phase III study. | 0 | 0 |
| 705 | 0 | 0 | 2386 2003 BLOOD 102(11):687A-687A Zangari M; Barlogie B; Lee CK; Kang SH; Fassas A; Thertulien R; Van Rhee F; Talamo G; Burns M; Anaissie EJ; Tricot G; Jacobson J Increment in bone phophatase (ALP) in myeloma patients during treatment with velcade, thalidomide and dexamethasome (VTD) is a strong predictor for response. | 0 | 0 |
| 706 | 0 | 0 | 2387 2003 BLOOD 102(11):687A-687A Latif T; Elson P; Karam MA; Reed J; Tahir K; Srkalovic G; Hussein MA Incidence of renal impairment (RI) in multiple myeloma (MM) patients receiving combination chemotherapy and thalidomide (Thal) with bisphosphonate therapy. | 0 | 0 |
| 707 | 0 | 0 | 2388 2003 BLOOD 102(11):689A-689A Hattori Y; Kakimoto T; Okamoto S; Iguchi T; Morita K; Tanigawara Y; Ikeda Y Plasma concentration of thalidomide and clinical efficacy in patients with multiple myeloma. | 0 | 0 |
| 708 | 0 | 0 | 2389 2003 BLOOD 102(11):691A-691A Feyler S; Jackson G; Rawstron A; El-Sherbiny YM; Snowden JA; Johnson RJ Thalidomide maintenance following high dose therapy in multiple myeloma: A UK myeloma forum phase 2 study. | 0 | 0 |
| 709 | 0 | 0 | 2390 2003 BLOOD 102(11):691A-692A Hoyer B; Fenk R; Steidl U; Kondakci M; Germing U; Haas R; Kobbe G Single agent thalidomide for treatment of first relapse following high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma. | 0 | 0 |
| 710 | 0 | 0 | 2391 2003 BLOOD 102(11):692A-692A Moehler T; Hillengass J; Gerull S; Benner A; Schlenzka J; Neben K; Egerer G; Schaefer H; Goerner M; He AD Thalidomide (T) and CED chemotherapy followed by stem cell transplantation for poor prognosis multiple myeloma. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 711 | 0 | 0 | 2392 2003 BLOOD 102(11):829A-830A Lentzsch S; Koh KR; Stirling D; Zenke M; Dorken B Immunomodulatory derivative of thalidomide (IMiD CC-4047) determine the lineage commitment of hematopoietic progenitors by down regulation of GATA-1 and modulation of cytokine secretion. | 0 | 0 |
| 712 | 0 | 0 | 2393 2003 BLOOD 102(11):903A-903A Mitsiades CS; Mitsiades N; McMullan CJ; Poulaki V; Shringarpure R; Hideshima T; Chauhan D; Treon SP; Richardson PG; Munshi NC; Joseph M; Libermann TA; Anderson KC Immunomodulatory thalidomide derivatives have activity against tumor cells from Waldenstrom's macroglobulinemia. | 0 | 0 |
| 713 | 0 | 0 | 2394 2003 BLOOD 102(11):923A-924A Elliott MA; Geyer SM; Camoriano JK; Kahanic SP; Alexander SJ; Medgyesy DC; Li CY; Tefferi A Low dose thalidomide (Td) treatment in myelofibrosis with myeloid metaplasia (MMM): An NCCTG study. | 0 | 0 |
| 714 | 0 | 0 | 2395 2003 BLOOD 102(11):938A-938A Anagnostopoulos A; Zervas K; Zomas A; Pouli A; Hamilos G; Anagnostopoulos N; Dimopoulos MA The International Prognostic Index (IPI) is predictive for survival in refractory or relapsed myeloma patients treated with thalidomide-based regimens. | 0 | 0 |
| 715 | 0 | 0 | 2396 2003 BLOOD 102(11):984A-984A Sahebi F; Somlo G; Kogut NM; Falk PM; Spielberger R; Parker PM; Krishnan A; Frankel P; Kosobayashi N; Forman SJ Feasibility and toxicity of maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma | 0 | 0 |
| 716 | 0 | 0 | 2397 2003 BLOOD 102(11):985A-986A Somlo G; Yamamoto N; Carter N; O'Donnell M; Snyder D; Sahebi F; Krishnan A; Fung H; Stein A; Spielberger R; Schriber J; Alvarnas J; Chow W; Nademance A; Jasmine Z; Stephen F High complete response rate is associated with improved progression-free and overall survival in 104 patients with multiple myeloma, treated with tandem cycle high-dose melphalan and busulfan/cytoxan, and maintenance interferon alpha-2 (IF) with, or without thalidomide (Thai) | 0 | 0 |
| 717 | 34 | 59 | 2126 2002 BLOOD REVIEWS 16(4):207-215 Strasser K; Ludwig H Thalidomide treatment in multiple myeloma | 3 | 4 |
| 718 | 2 | 7 | 479 1969 BOLLETTINO DELLA SOCIETA ITALIANA DI BIOLOGIA SPERIMENTALE 45(19):1268-& RINALDI L THALIDOMIDE AND MORPHOGENETIC PROCESSES IN ADULT - INFLUENCE OF THALIDOMIDE ON TAIL REGENERATION IN NEWT (TRITURUS-CRISTATUS) | 0 | 0 |
| 719 | 0 | 1 | 480 1969 BOLLETTINO DELLA SOCIETA ITALIANA DI BIOLOGIA SPERIMENTALE 45(20A):62-& LAI P; PALMIERI G INFLUENCE OF THALIDOMIDE ON REPRODUCTIVE CAPACITY OF CHICKENS | 0 | 0 |
| 720 | 0 | 0 | 2589 2004 BONE 34:S97-S97 Spencer A; Roberts A; Bailey M; Schran H; Lynch K Safety and pharmacokinetic analysis of zoledronic acid in a multicentre randomised trial of post-transplant thalidomide maintenance therapy for multiple myeloma | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 721 | 11 | 19 | 963 1988 BONE MARROW TRANSPLANTATION 3(5):393-398 VOGELSANG GB; HESS AD; SANTOS GW THALIDOMIDE FOR TREATMENT OF GRAFT-VERSUS-HOST DISEASE | 31 | 38 |
| 722 | 4 | 6 | 990 1989 BONE MARROW TRANSPLANTATION 4(5):598-598 HEATON DC FAILURE OF THALIDOMIDE TO CONTROL BRONCHIOLITIS OBLITERANS POST BONE-MARROW TRANSPLANT | 1 | 3 |
| 723 | 4 | 5 | 1089 1993 BONE MARROW TRANSPLANTATION 11(3):251-252 LOPEZ J; ULIBARRENA C; GARCIALARANA J; ODRIOZOLA J; DEOTEYZA JP; SASTRE JL; NAVARRO JL THALIDOMIDE AS THERAPY FOR INTESTINAL CHRONIC GVHD | 6 | 9 |
| 724 | 33 | 38 | 1090 1993 BONE MARROW TRANSPLANTATION 12:S26-S28 EHNINGER G; EGER K; STUHLER A; SCHULER U THALIDOMIDE - THE NEED FOR A NEW CLINICAL-EVALUATION OF AN OLD DRUG | 7 | 8 |
| 725 | 27 | 42 | 1124 1994 BONE MARROW TRANSPLANTATION 14(6):937-942 COLE CH; ROGERS PCJ; PRITCHARD S; PHILLIPS G; CHAN KW THALIDOMIDE IN THE MANAGEMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE IN CHILDREN FOLLOWING BONE-MARROW TRANSPLANTATION | 25 | 30 |
| 726 | 10 | 13 | 1249 1996 BONE MARROW TRANSPLANTATION 17(2):291-293 Forsyth CJ; Cremer PD; Torzillo P; Iland HJ; Young GAR Thalidomide responsive chronic pulmonary GVHD | 8 | 14 |
| 727 | 2 | 5 | 1317 1997 BONE MARROW TRANSPLANTATION 19(1):95-96 Chen F; Tsang K; Liang R Thalidomide-responsive chronic pulmonary GVHD | 0 | 0 |
| 728 | 0 | 0 | 1416 1998 BONE MARROW TRANSPLANTATION 21:S113-S113 Anagnostopoulos A; Fassas A; Giannaki E; Sakellari I; Tzarou V; Smias C; Lalayanni C; Papaioannou G; Gakos E Treatment of resistant chronic GVHD with thalidomide. | 0 | 0 |
| 729 | 14 | 23 | 1417 1998 BONE MARROW TRANSPLANTATION 21(6):577-581 Rovelli A; Arrigo C; Nesi F; Balduzzi A; Nicolini B; Locasiulli A; Vassallo E; Miniero R; Uderzo C The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children | 26 | 36 |
| 730 | 5 | 7 | 1418 1998 BONE MARROW TRANSPLANTATION 22(9):933-934 Sastry PSRK; Powles RL Thalidomide for chronic GVHD | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 731 | 1 | 1 | 1419 1998 BONE MARROW TRANSPLANTATION 22(9):934-934 Kami M; Ogawa S; Mitani K; Hirai H Thalidomide for chronic GVHD - Reply | 0 | 0 |
| 732 | 2 | 6 | 1679 2000 BONE MARROW TRANSPLANTATION 25(12):1319-1320 Zomas A; Anagnostopoulos N; Dimopoulos MA Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent | 18 | 32 |
| 733 | 9 | 19 | 1680 2000 BONE MARROW TRANSPLANTATION 26(8):865-869 Browne PV; Weisdorf DJ; DeFor T; Miller WJ; Davies SM; Filipovich A; McGlave PB; Ramsay NKC; Wagner J; Enright H Response to thalidomide therapy in refractory chronic graft-versus-host disease | 11 | 17 |
| 734 | 0 | 0 | 1879 2001 BONE MARROW TRANSPLANTATION 27:S251-S252 Hus M; Dmoszynska A; Legiec W; Jawniak D; Soroka-Wojtaszko M; Manko J Thalidomide as a preparative regimen and late stem cell transplantation in patients with relapsed or refractory multiple myeloma | 0 | 0 |
| 735 | 4 | 4 | 1880 2001 BONE MARROW TRANSPLANTATION 27(2):229-230 Schlossberg H; Klumpp T; Sabol P; Herman J; Mangan K Severe cutaneous ulceration following treatment with thalidomide for GVHD | 0 | 1 |
| 736 | 10 | 38 | 1881 2001 BONE MARROW TRANSPLANTATION 28(12):1145-1150 Biagi JJ; Mileshkin L; Grigg AP; Westerman DW; Prince HM Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation | 3 | 5 |
| 737 | 0 | 0 | 2127 2002 BONE MARROW TRANSPLANTATION 29:S100-S100 Mohty M; Stoppa A; Blaise D; Isnardon D; Gastaut J; Olive D; Gaugler B Differential regulation of dendritic cell function by the Immunomodulatory drug thalidomide: implications for multiple myeloma therapy | 0 | 0 |
| 738 | 0 | 0 | 2128 2002 BONE MARROW TRANSPLANTATION 29:S104-S104 Patriarca F; Fill C; Sperotto A; Damiani D; Zaja F; Cerno M; Fanin R Thalidomide overcomes VAD chemoresistance and allows PBSC collection in 3 multiple myeloma patients | 0 | 0 |
| 739 | 0 | 0 | 2129 2002 BONE MARROW TRANSPLANTATION 29:S255-S256 Dagan L; Ovadia R; Taou D; Bar L The introduction of thalidomide (T) in BMT programs for patients with multiple myeloma (MM): encouraging results and a challenge for nursing team | 0 | 0 |
| 740 | 9 | 19 | 2130 2002 BONE MARROW TRANSPLANTATION 29(7):577-580 Ahmad I; Islam T; Chanan-Khan A; Hahn T; Wentling D; Becker JL; McCarthy PL; Alam AR Myeloma - Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT | 6 | 7 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 741 | 0 | 0 | 2398 2003 BONE MARROW TRANSPLANTATION 31:S76-S77 Tueger S; Chen F; Ahsan G; Andrews V; Kazmi M; Madrigal J; Schey S Thalidomide-induced remission of refractory diffuse large B-cell lymphoma post-allogeneic SCT - a result of modulation of CTL function? | 0 | 0 |
| 742 | 0 | 0 | 2399 2003 BONE MARROW TRANSPLANTATION 31:S78-S79 Patriarca F; Sperotto A; Prosdocimo S; Geromin A; Zaja F; Fili C; Cerno M; Fanin R Thalidomide before autologous stem cell transplantation in VAD-refractory multiple myeloma patients | 0 | 0 |
| 743 | 2 | 6 | 2400 2003 BONE MARROW TRANSPLANTATION 31(11):1065-1065 Pitini V; Arrigo C; Aloi G; Micali C; La Gattuta G Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT | 0 | 0 |
| 744 | 0 | 1 | 2401 2003 BONE MARROW TRANSPLANTATION 31(11):1067-1067 Alam AR Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT - Reply to the letter by V Pitini | 0 | 0 |
| 745 | 13 | 35 | 2402 2003 BONE MARROW TRANSPLANTATION 32(2):165-170 Kulkarni S; Powles R; Sirohi B; Treleaven J; Saso R; Horton C; Atra A; Ortin M; Rudin C; Goyal S; Sankpal S; Meller S; Pinkerton CR; Mehta J; Singhal S Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease | 0 | 1 |
| 746 | 6 | 6 | 2403 2003 BONE MARROW TRANSPLANTATION 32(3):343-343 Milone JH; Prates V; Bordone J; Napal J; Garcia C Response to single-agent thalidomide and eligibility to undergo autotransplant for patients with multiple myeloma refractory to VAD | 0 | 0 |
| 747 | 11 | 28 | 2404 2003 BONE MARROW TRANSPLANTATION 32(6):587-592 Ghobrial IM; Dispenzieri A; Bundy KL; Gastineau DA; Rajkumar SV; Therneau TM; Lacy MQ; Witzig TE; Litzow MR; Christensen BR; Hayman S; Pribula CG; Gertz MA Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma | 1 | 1 |
| 748 | 0 | 0 | 2590 2004 BONE MARROW TRANSPLANTATION 33:S156-S156 Yakoub-Agha I; Mohty M; Attal M; Marit G; Bulabois C; Sotto JJ; Gratecos N; Rio B; Vernant JP; Facon T; Jouet JP; Intergrp Francophne Myelome & SGFM Thalidomide as salvage therapy for relapsed multiple myeloma after allogeneic stem cell transplantation | 0 | 0 |
| 749 | 0 | 0 | 2591 2004 BONE MARROW TRANSPLANTATION 33:S156-S157 Hardan I; Kneller A; Shimoni A; Berkowicz M; Avigdor A; Yeshurun M; Raanani P; Davidowich Y; Shemtov N; Ben Bassat I; Nagler A Salvage of multiple myeloma patients relapse after an autologous stem cell transplantation, in the era of thalidomide and reduced-intensity allogeneic stem cell transplantation | 0 | 0 |
| 750 | 0 | 0 | 2592 2004 BONE MARROW TRANSPLANTATION 33:S160-S161 Ciepluch H; Knopinska-Posluszny W; Czyz J; Hellmann A Employment of autologous transplantation of progenitor cells following effective treatment with thalidomide of patients with multiple myeloma resistant to conventional chemotherapy | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 751 | 0 | 0 | 2593 2004 BONE MARROW TRANSPLANTATION 33:S161-S161 Trojan A; Giger R; Rist N; Jager D; Taverna C Thalidomide stimulates peptide specific CD8+T-cells against viral epitopes | 0 | 0 |
| 752 | 0 | 0 | 2594 2004 BONE MARROW TRANSPLANTATION 33:S162-S162 Hoyer B; Fenk R; Steidl U; Germing U; Haas R; Kobbe G Treatment of patients with multiple myeloma in first relapse after high-dose chemotherapy with single agent thalidomide - duration of first remission is the major prognostic factor for EFS and OS | 0 | 0 |
| 753 | 0 | 0 | 2595 2004 BONE MARROW TRANSPLANTATION 33:S165-S165 Offidani M; Marconi M; Corvatta L; Malerba L; Olivieri A; Mele A; Galieni P; Centurioni R; Alesiani F; Candela M; Leoni P Combination thalidomide, doxil and dexamethasone as salvage therapy for patients relapsed after tandem autotransplant | 0 | 0 |
| 754 | 0 | 0 | 2596 2004 BONE MARROW TRANSPLANTATION 33:S356-S356 Alegre A; Martinez-Chamorro C; Escudero A; Aguado B; Osorio S; Nistal S; Cordoba R; Gil-Fernandez J; Sanchez-Godoy P; Burgaleta C; Casado F; Fernandez-Ranada JM Maintenance treatment with bisphosphonates plus interferon plus dexamethasone plus thalidomide (quadruple maintenance) after autologous peripheral blood stem cell transplantion in multiple myeloma: preliminary results | 0 | 0 |
| 755 | 6 | 17 | 802 1983 BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH 16(2):105-109 SCHMIDT M; SALZANO FM CLINICAL-STUDIES ON TEENAGE BRAZILIAN VICTIMS OF THALIDOMIDE | 2 | 3 |
| 756 | 4 | 28 | 1177 1995 BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH 28(10):1069-1076 AARESTRUP FM; GONCALVESDACOSTA SC; SARNO EN THE EFFECT OF THALIDOMIDE ON BCG-INDUCED GRANULOMAS IN MICE | 2 | 9 |
| 757 | 6 | 35 | 1318 1997 BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH 30(10):1199-1207 Moreira AL; Wang J; Sarno EN; Kaplan G Thalidomide protects mice against LPS-induced shock | 11 | 13 |
| 758 | 3 | 38 | 2597 2004 BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH 37(4):485-492 Arruda MSP; Richini VB; Oliveira SMA; Vilani-Moreno FR Experimental murine mycobacteriosis: evaluation of the functional activity of alveolar macrophages in thalidomide-treated mice | 0 | 0 |
| 759 | 6 | 15 | 424 1967 BRITISH JOURNAL OF CANCER 21(2):331-& ROE FJC; WALTERS MA; MITCHLEY BC TUMOUR-INCIDENCE IN PROGENY OF THALIDOMIDE-TREATED MICE | 0 | 2 |
| 760 | 5 | 25 | 1178 1995 BRITISH JOURNAL OF CANCER 72(2):339-343 CHING LM; XU ZF; GUMMER BH; PALMER BD; JOSEPH WR; BAGULEY BC EFFECT OF THALIDOMIDE ON TUMOR-NECROSIS-FACTOR PRODUCTION AND ANTITUMOR-ACTIVITY INDUCED BY 5,6-DIMETHYLXANTHENONE-4-ACETIC ACID | 25 | 41 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 761 | 8 | 24 | 1420 1998 BRITISH JOURNAL OF CANCER 78(3):336-343 Ching LM; Browne WL; Tchernegovski R; Gregory T; Baguley BC; Palmer BD Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity | 16 | 26 |
| 762 | 7 | 42 | 1521 1999 BRITISH JOURNAL OF CANCER 79(1):114-118 Verheul HMW; Panigrahy D; Yuan J; D'Amato RJ Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits | 16 | 31 |
| 763 | 22 | 42 | 1522 1999 BRITISH JOURNAL OF CANCER 80(5-6):716-723 Cao Z; Joseph WR; Browne WL; Mountjoy KG; Palmer BD; Baguley BC; Ching LM Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid | 10 | 25 |
| 764 | 13 | 38 | 1681 2000 BRITISH JOURNAL OF CANCER 82(4):812-817 Eisen T; Boshoff C; Mak I; Sapunar F; Vaughan MM; Pyle L; Johnston SRD; Ahern R; Smith IE; Gore ME Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer | 76 | 127 |
| 765 | 0 | 0 | 1682 2000 BRITISH JOURNAL OF CANCER 83:31-31 Stebbing J; Benson C; Eisen T; Mak I; Pyle L; Smalley K; Gore ME A phase II study of high dose oral thalidomide in patients with metastatic renal cell carcinoma (RCC) or metastatic melanoma (MM) | 0 | 0 |
| 766 | 2 | 4 | 1882 2001 BRITISH JOURNAL OF CANCER 85:25-25 Dalgleish A; Marriott J; Czajka A; Clarke I; Dredge K; Muller G; Stirling D New thalidomide analogues; Anti-cancer, anti-angiogenic and immunostimulatory. | 0 | 0 |
| 767 | 16 | 37 | 1883 2001 BRITISH JOURNAL OF CANCER 85(7):953-958 Stebbing J; Benson C; Eisen T; Pyle L; Smalley K; Bridle H; Mak I; Sapunar F; Ahern R; Gore ME The treatment of advanced renal cell cancer with high-dose oral thalidomide | 18 | 30 |
| 768 | 0 | 0 | 2131 2002 BRITISH JOURNAL OF CANCER 86:S26-S26 Marriott JB; Clarke IA; Dredge K; Pandha H; Kristaleit H; Polychronis A; Muller GW; Stirling D; Dalgleish AG Thalidomide analogue CDC-501 is safe and well tolerated by patients with end stage cancer and shows evidence of clinical responses and extensive immune activation | 3 | 3 |
| 769 | 0 | 0 | 2132 2002 BRITISH JOURNAL OF CANCER 86:S42-S42 Braybrooke JP; Madhusudan S; Blann A; Wilner S; Flanagan E; Jenkins A; Echeta C; Perren T; Ganesan TS Randomised phase two study of carboplatin versus carboplatin and thalidomide in patients with ovarian cancer, with evaluation of potential surrogate markers of angiogenesis. | 0 | 0 |
| 770 | 0 | 0 | 2133 2002 BRITISH JOURNAL OF CANCER 86:S117-S118 Marriott JB; Clarke IA; Czajka A; Dredge K; Childs K; Man HW; Schafer P; Govinda S; Muller GW; Stirling D; Dalgleish AG A novel subclass of thalidomide analogue with anti-solid tumour activity in which caspase dependent apoptosis is associated with altered expression of BCL-2 family proteins | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 771 | 10 | 36 | 2134 2002 BRITISH JOURNAL OF CANCER 87(10):1166-1172 Dredge K; Marriott JB; Macdonald CD; Man HW; Chen R; Muller GW; Stirling D; Dalgleish AG Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects | 9 | 15 |
| 772 | 0 | 0 | 2405 2003 BRITISH JOURNAL OF CANCER 88:S28-S28 Dalgleish A; Schey S; Jones R; Raj K; Dredge K; Streetly M; Marriott B Thalidomide analogues CC-5013 and CC-4047 induce T cell activation and IL-12 production in patients with both solid tumours and relapsed and refractory multiple myeloma. | 0 | 0 |
| 773 | 0 | 0 | 2406 2003 BRITISH JOURNAL OF CANCER 88:S46-S46 Malpas J; Chaplin T; Sanmugathasan A; Liu W In vitro activity of S-thalidomide against multiple myeloma cells: A gene and protein expression profile. | 0 | 0 |
| 774 | 8 | 20 | 2407 2003 BRITISH JOURNAL OF CANCER 88(6):822-827 Drake MJ; Robson W; Mehta P; Schofield I; Neal DE; Leung HY An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer | 3 | 9 |
| 775 | 32 | 40 | 2598 2004 BRITISH JOURNAL OF CANCER 90(5):955-961 Bartlett JB; Michael A; Clarke IA; Dredge K; Nicholson S; Kristeleit H; Polychronis A; Pandha H; Muller GW; Stirling DI; Zeldis J; Dalgleish AG Phase 1 study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers | 1 | 1 |
| 776 | 0 | 3 | 964 1988 BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 26(5):P623-P623 HAGUE D; SMITH RL ENIGMATIC PROPERTIES OF (+/-)-THALIDOMIDE - AN EXAMPLE OF A STABLE RACEMIC COMPOUND | 6 | 7 |
| 777 | 3 | 8 | 779 1982 BRITISH JOURNAL OF DERMATOLOGY 107(1):83-86 NAAFS B; BAKKERS EJM; FLINTERMAN J; FABER WR THALIDOMIDE TREATMENT OF SUB-ACUTE CUTANEOUS LUPUS-ERYTHEMATOSUS | 30 | 44 |
| 778 | 0 | 0 | 803 1983 BRITISH JOURNAL OF DERMATOLOGY 108(1):109-109 HASPER MF THE EFFECT OF THALIDOMIDE IN THE TREATMENT OF LUPUS-ERYTHEMATOSUS | 0 | 0 |
| 779 | 5 | 8 | 804 1983 BRITISH JOURNAL OF DERMATOLOGY 108(4):461-466 KNOP J; BONSMANN G; HAPPLE R; LUDOLPH A; MATZ DR; MIFSUD EJ; MACHER E THALIDOMIDE IN THE TREATMENT OF 60 CASES OF CHRONIC DISCOID LUPUS-ERYTHEMATOSUS | 78 | 109 |
| 780 | 7 | 21 | 805 1983 BRITISH JOURNAL OF DERMATOLOGY 108(4):467-471 LOVELL CR; HAWK JLM; CALNAN CD; MAGNUS IA THALIDOMIDE IN ACTINIC PRURIGO | 21 | 41 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 781 | 2 | 3 | 806 1983 BRITISH JOURNAL OF DERMATOLOGY 109(4):479-480 NAAFS B; FABER WR THALIDOMIDE | 0 | 0 |
| 782 | 1 | 3 | 846 1984 BRITISH JOURNAL OF DERMATOLOGY 111(1):125-126 AYRES S THALIDOMIDE OR VITAMIN-E THERAPY FOR DISCOID LUPUS-ERYTHEMATOSUS | 1 | 2 |
| 783 | 17 | 30 | 878 1985 BRITISH JOURNAL OF DERMATOLOGY 112(4):475-480 WULFF CH; HOYER H; ASBOEHANSEN G; BRODTHAGEN H DEVELOPMENT OF POLYNEUROPATHY DURING THALIDOMIDE THERAPY | 66 | 85 |
| 784 | 2 | 2 | 879 1985 BRITISH JOURNAL OF DERMATOLOGY 112(5):632-632 KURKCUOGLU N; ATAKAN N; EKSIOGLU M THALIDOMIDE IN THE TREATMENT OF RECURRENT NECROTIC MUCOCUTANEOUS APHTHAE | 13 | 16 |
| 785 | 9 | 13 | 880 1985 BRITISH JOURNAL OF DERMATOLOGY 113:141-144 POWELL RJ; ALLEN BR; JENKINS JS; STEELE L; HUNNEYBALL I; MAURICE PDL; LITTLEWOOD SM INVESTIGATION AND TREATMENT OF OROGENITAL ULCERATION - STUDIES ON A POSSIBLE MODE OF ACTION OF THALIDOMIDE | 7 | 9 |
| 786 | 13 | 27 | 915 1986 BRITISH JOURNAL OF DERMATOLOGY 115(3):367-370 RAMSELAAR CG; BOONE RM; KLUINNELEMANS HC THALIDOMIDE IN THE TREATMENT OF NEURO-BEHCETS SYNDROME | 10 | 20 |
| 787 | 8 | 15 | 916 1986 BRITISH JOURNAL OF DERMATOLOGY 115(6):677-680 MAURICE PDL; BARKLEY ASJ; ALLEN BR THE EFFECT OF THALIDOMIDE ON ARACHIDONIC-ACID METABOLISM IN HUMAN POLYMORPHONUCLEAR LEUKOCYTES AND PLATELETS | 5 | 5 |
| 788 | 2 | 34 | 1036 1991 BRITISH JOURNAL OF DERMATOLOGY 125(1):62-67 BURROWS NP; WALPORT MJ; HAMMOND AH; DAVEY N; JONES RR LUPUS-ERYTHEMATOSUS PROFUNDUS WITH PARTIAL C4-DEFICIENCY RESPONDING TO THALIDOMIDE | 12 | 23 |
| 789 | 4 | 6 | 1055 1992 BRITISH JOURNAL OF DERMATOLOGY 126(1):92-93 MOISSON YF; JANIER M; CIVATTE J THALIDOMIDE FOR RECURRENT ERYTHEMA MULTIFORME | 9 | 12 |
| 790 | 4 | 4 | 1179 1995 BRITISH JOURNAL OF DERMATOLOGY 132(1):168-168 MEUNIER L; MARCK Y; RIBEYRE C; MEYNADIER J ADULT CUTANEOUS LANGERHANS CELL HISTIOCYTOSIS - REMISSION WITH THALIDOMIDE TREATMENT | 9 | 20 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 791 | 9 | 12 | 1884 2001 BRITISH JOURNAL OF DERMATOLOGY 144(2):227-228 Allen BR Thalidomide | 4 | 4 |
| 792 | 30 | 32 | 1885 2001 BRITISH JOURNAL OF DERMATOLOGY 144(2):310-315 Chave TA; Finlay AY; Knight AG; All-Wales Dermatology Audit Comm Thalidomide usage in Wales: the need to follow guidelines | 1 | 1 |
| 793 | 4 | 4 | 1886 2001 BRITISH JOURNAL OF DERMATOLOGY 144(6):1292-1293 Passeron T; Lacour JP; Murr D; Ortonne JP Thalidomide-induced amenorrhoea: two cases | 4 | 4 |
| 794 | 4 | 6 | 2135 2002 BRITISH JOURNAL OF DERMATOLOGY 146(6):1112-1113 Pouaha J; Martin S; Reichert-Penetrat S; Trechot P; Barbaud A; Schmutz JL Thalidomide and sexual dysfunction in men | 0 | 0 |
| 795 | 4 | 9 | 2408 2003 BRITISH JOURNAL OF DERMATOLOGY 148(3):601-602 Worm M; Kolde G Schnitzler's syndrome: successful treatment of two patients using thalidomide | 0 | 0 |
| 796 | 5 | 11 | 2409 2003 BRITISH JOURNAL OF DERMATOLOGY 148(5):1060-1061 Tjiu JW; Hsiao CH; Tsai TF Cutaneous Rosai-Dorfman disease: remission with thalidomide treatment | 0 | 0 |
| 797 | 0 | 0 | 2410 2003 BRITISH JOURNAL OF DERMATOLOGY 149:81-81 Strauss RM; Bate J; Clayton T; Gooi J; Darling J; Newton-Bishop JA A child with laryngo-onycho-cutaneous syndrome successfully treated with thalidomide | 0 | 0 |
| 798 | 11 | 14 | 2411 2003 BRITISH JOURNAL OF DERMATOLOGY 149(2):432-433 Dobson CM; Parslew RA Exacerbation of psoriasis by thalidomide in Behcet's syndrome | 0 | 0 |
| 799 | 0 | 1 | 516 1971 BRITISH JOURNAL OF EDUCATIONAL PSYCHOLOGY 41(N):347-347 MOORE EM CHALLENGE OF THALIDOMIDE - PRINGLE,MLK AND FIDDES,DO | 0 | 0 |
| 800 | 0 | 12 | 363 1966 BRITISH JOURNAL OF EXPERIMENTAL PATHOLOGY 47(2):186-& PEARN JH; VICKERS TH RABBIT THALIDOMIDE EMBRYOPATHY | 8 | 12 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 801 | 2 | 7 | 425 1967 BRITISH JOURNAL OF EXPERIMENTAL PATHOLOGY 48(1):107-& VICKERS TH THALIDOMIDE EMBRYOPATHY IN HYBRID RABBITS | 8 | 20 |
| 802 | 6 | 15 | 426 1967 BRITISH JOURNAL OF EXPERIMENTAL PATHOLOGY 48(2):150-& COOK MJ; MOORE DF EFFECT OF THALIDOMIDE ON DEVELOPING RAT FOETUS | 1 | 4 |
| 803 | 5 | 8 | 427 1967 BRITISH JOURNAL OF EXPERIMENTAL PATHOLOGY 48(6):579-& VICKERS TH CONCERNING MORPHOGENESIS OF THALIDOMIDE DYSMELIA IN RABBITS | 12 | 18 |
| 804 | 3 | 8 | 452 1968 BRITISH JOURNAL OF EXPERIMENTAL PATHOLOGY 49(2):179-& VICKERS TH CARDIOVASCULAR MALFORMATIONS IN RABBIT THALIDOMIDE EMBRYOPATHY | 2 | 5 |
| 805 | 7 | 20 | 498 1970 BRITISH JOURNAL OF EXPERIMENTAL PATHOLOGY 51(3):286-& VICKERS TH ALIMENTARY TRACT MALFORMATIONS IN RABBIT THALIDOMIDE EMBRYOPATHY | 0 | 2 |
| 806 | 1 | 1 | 453 1968 BRITISH JOURNAL OF HAEMATOLOGY 15(3):322-& LEWIS HBM; ALBERTRE.F; WALKER W COLD HAEMAGGLUTINATION DISEASE TREATED BY THALIDOMIDE | 0 | 5 |
| 807 | 14 | 20 | 1037 1991 BRITISH JOURNAL OF HAEMATOLOGY 78(1):23-27 HENEY D; NORFOLK DR; WHEELDON J; BAILEY CC; LEWIS IJ; BARNARD DL THALIDOMIDE TREATMENT FOR CHRONIC GRAFT-VERSUS-HOST DISEASE | 59 | 72 |
| 808 | 1 | 7 | 1683 2000 BRITISH JOURNAL OF HAEMATOLOGY 108(2):391-393 Kneller A; Raanani P; Hardan I; Avigdor A; Levi I; Berkowicz M; Ben-Bassat I Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug | 53 | 75 |
| 809 | 8 | 19 | 1684 2000 BRITISH JOURNAL OF HAEMATOLOGY 109(1):89-96 Juliusson G; Celsing F; Turesson I; Lenhoff S; Adriansson M; Malm C Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma | 88 | 117 |
| 810 | 4 | 4 | 1685 2000 BRITISH JOURNAL OF HAEMATOLOGY 110(3):754-754 Gutheil J; Finucane D Thalidomide therapy in refractory solid tumour patients | 10 | 13 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 811 | 1 | 1 | 1686 2000 BRITISH JOURNAL OF HAEMATOLOGY 111(3):986-986 Myers B; Crouch D; Dolan G Thalidomide treatment in advanced refractory myeloma | 5 | 5 |
| 812 | 5 | 12 | 1887 2001 BRITISH JOURNAL OF HAEMATOLOGY 113(2):422-424 Blade J; Perales M; Rosinol L; Tuset M; Montoto S; Esteve O; Cobo F; Villela L; Rafel M; Nomdedeu B; Montserrat E Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas | 18 | 19 |
| 813 | 12 | 22 | 1888 2001 BRITISH JOURNAL OF HAEMATOLOGY 114(1):78-83 Barosi G; Grossi A; Comotti B; Musto P; Gamba G; Marchetti M Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia | 12 | 23 |
| 814 | 1 | 3 | 1889 2001 BRITISH JOURNAL OF HAEMATOLOGY 114(1):245-245 Myers B; Grimley C; Dolan G Thalidomide and low-dose dexamethasone in myeloma treatment | 2 | 3 |
| 815 | 3 | 4 | 1890 2001 BRITISH JOURNAL OF HAEMATOLOGY 115(1):234-234 Myers B; Grimley C; Crouch D; Dolan G Lack of response to thalidomide in plasmacytomas | 2 | 4 |
| 816 | 2 | 12 | 1891 2001 BRITISH JOURNAL OF HAEMATOLOGY 115(2):313-315 Canepa L; Ballerini F; Varaldo R; Quintino S; Reni L; Clavio M; Miglino M; Pierri I; Gobbi M Thalidomide in agnogenic and secondary myelofibrosis | 11 | 16 |
| 817 | 3 | 8 | 1892 2001 BRITISH JOURNAL OF HAEMATOLOGY 115(2):484-485 Biagi JJ; Prince HM Thalidomide is effective for extramedullary relapse of multiple myeloma postallogeneic bone marrow transplantation | 1 | 1 |
| 818 | 3 | 12 | 1893 2001 BRITISH JOURNAL OF HAEMATOLOGY 115(3):605-608 Neben K; Moehler T; Kraemer A; Benner A; Egerer G; Ho AD; Goldschmidt H Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion | 19 | 29 |
| 819 | 8 | 53 | 1894 2001 BRITISH JOURNAL OF HAEMATOLOGY 115(4):881-894 Zorat F; Shetty V; Dutt D; Lisak L; Nascimben F; Allampallam K; Dar S; York A; Gezer S; Venugopal P; Raza A The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes | 13 | 22 |
| 820 | 12 | 36 | 2136 2002 BRITISH JOURNAL OF HAEMATOLOGY 117(2):288-296 Elliott MA; Mesa RA; Li CY; Hook CC; Ansell SM; Levitt RM; Geyer SM; Tefferi A Thalidomide treatment in myelofibrosis with myeloid metaplasia | 12 | 21 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 821 | 4 | 5 | 2137 2002 BRITISH JOURNAL OF HAEMATOLOGY 117(4):996-997 Bauduer F Efficacy of thalidomide in the treatment of VAD-refractory plasma cell leukaemia appearing after autologous stem cell transplantation for multiple myeloma | 0 | 0 |
| 822 | 4 | 4 | 2138 2002 BRITISH JOURNAL OF HAEMATOLOGY 118(1):347-347 Myers B; Dolan G Analysis of durability of response to thalidomide treatment for relapsed myeloma patients | 1 | 1 |
| 823 | 8 | 12 | 2139 2002 BRITISH JOURNAL OF HAEMATOLOGY 119(1):128-130 Wilson EA; Jobanputra S; Jackson R; Parker AN; McQuaker IG Response to thalidomide in chemotherapy-resistant mantle cell lymphoma: a case report | 1 | 3 |
| 824 | 3 | 5 | 2140 2002 BRITISH JOURNAL OF HAEMATOLOGY 119(1):275-275 Pitini V; Teti D; Arrigo C; Aloi G Thalidomide treatment of relapsed multiple myeloma patients and changes in circulating VEGF and bFGF | 0 | 0 |
| 825 | 0 | 4 | 2141 2002 BRITISH JOURNAL OF HAEMATOLOGY 119(2):576-577 Jones SG; Dolan G; Lengyel K; Myers B Severe increase in creatinine with hypocalcaemia in thalidomide-treated myeloma patients receiving zoledronic acid infusions | 0 | 2 |
| 826 | 6 | 7 | 2142 2002 BRITISH JOURNAL OF HAEMATOLOGY 119(3):883-884 Gonzalez-Porras JR; Gonzalez M; Garcia-Sanz R; San Miguel JF Thalidomide in combination with cyclophosphamide and dexamethasone (ThaCyDex) is effective in soft-tissue plasmacytomas | 0 | 0 |
| 827 | 19 | 50 | 2412 2003 BRITISH JOURNAL OF HAEMATOLOGY 120(1):18-26 Cavenagh JD; Oakervee H; UK Myeloma Forum; BSCH Haematology Oncology Task For Thalidomide in multiple myeloma: Current status and future prospects | 12 | 15 |
| 828 | 5 | 12 | 2413 2003 BRITISH JOURNAL OF HAEMATOLOGY 121(1):101-103 Steurer M; Sudmeier I; Stauder R; Gastl G Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha | 3 | 5 |
| 829 | 3 | 5 | 2414 2003 BRITISH JOURNAL OF HAEMATOLOGY 121(1):191-192 Younis TH Reversible pulmonary hypertension and thalidomide therapy for multiple myeloma | 1 | 2 |
| 830 | 4 | 12 | 2415 2003 BRITISH JOURNAL OF HAEMATOLOGY 121(5):768-771 Anagnostopoulos A; Weber D; Rankin K; Delasalle K; Alexanian R Thalidomide and dexamethasone for resistant multiple myeloma | 11 | 16 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 831 | 4 | 7 | 2416 2003 BRITISH JOURNAL OF HAEMATOLOGY 122(1):159-160 Santos AB; Llamas P; Roman A; Prieto E; de Ona R; de Velasco JF; Tomas JF Evaluation of thrombophylic states in myeloma patients receiving thalidomide: A reasonable doubt | 1 | 1 |
| 832 | 5 | 6 | 2417 2003 BRITISH JOURNAL OF HAEMATOLOGY 122(1):160-161 Harris E; Behrens J; Samson D; Rahemtulla A; Russell NH; Byrne JL Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia | 2 | 3 |
| 833 | 19 | 40 | 2418 2003 BRITISH JOURNAL OF HAEMATOLOGY 122(4):607-616 Kropff MH; Lang N; Bisping G; Domine N; Innig G; Hentrich M; Mitterer M; Sudhoff T; Fenk R; Straka C; Heinecke A; Koch OM; Ostermann H; Berdel WE; Kienast J Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma | 4 | 8 |
| 834 | 4 | 10 | 2419 2003 BRITISH JOURNAL OF HAEMATOLOGY 123(2):305-308 Thompson MA; Witzig TE; Kumar S; Timm MM; Haug J; Fonseca R; Greipp PR; Lust JA; Rajkumar SV Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma | 2 | 4 |
| 835 | 9 | 20 | 2420 2003 BRITISH JOURNAL OF HAEMATOLOGY 123(3):436-441 Thomas DA; Estey E; Giles FJ; Faderl S; Cortes J; Keating M; O'Brien S; Albitar M; Kantarjian H Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia | 0 | 0 |
| 836 | 1 | 1 | 2421 2003 BRITISH JOURNAL OF HAEMATOLOGY 123(3):563-563 Younis T; Alam A; Paplham P; Spangenthal E; McCarthy P Reversible pulmonary hypertension and thalidomide therapy for multiple myeloma (vol 121, pg 191, 2003) | 0 | 1 |
| 837 | 1 | 3 | 2422 2003 BRITISH JOURNAL OF HAEMATOLOGY 123(4):747-748 Mileshkin L; Prince HM; Seymour JF; Biagi JJ Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide | 0 | 0 |
| 838 | 0 | 3 | 2423 2003 BRITISH JOURNAL OF HAEMATOLOGY 123(4):748-748 Luminari S; Federico M; Baldini L Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide - Response to Mileshkin et al. | 0 | 0 |
| 839 | 0 | 0 | 2599 2004 BRITISH JOURNAL OF HAEMATOLOGY 125:20-20 Morris TCM; Hull DR; Boyd C; Jones FCG; Kettle PJ; Drake M; McLoughlin R; Quinn J Clarithromycin, dexamethasone and low dose thalidomide (CDT) is effective therapy in relapsed/refractory myeloma and useful in patients with cytopenias | 0 | 0 |
| 840 | 4 | 5 | 2600 2004 BRITISH JOURNAL OF HAEMATOLOGY 125(1):96-97 Fakhouri F; Guerraoui H; Presne C; Peltier J; Delarue R; Muret P; Knebelmann B Thalidomide in patients with multiple myeloma and renal failure | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 841 | 11 | 15 | 2601 2004 BRITISH JOURNAL OF HAEMATOLOGY 125(2):149-155 Waage A; Gimsing P; Juliusson G; Turesson I; Gulbrandsen N; Eriksson T; Hjorth M; Nielsen JL; Lenhoff S; Westin J; Wisloff F; Nordic Myeloma Study Grp Early response predicts thalidomide efficiency in patients with advanced multiple myeloma | 0 | 0 |
| 842 | 5 | 8 | 965 1988 BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY 95(7):717-719 MAOURIS PG; HIRSCH PJ PREGNANCY IN WOMEN WITH THALIDOMIDE-INDUCED DISABILITIES - CASE-REPORT AND A QUESTIONNAIRE STUDY | 0 | 4 |
| 843 | 9 | 9 | 2143 2002 BRITISH JOURNAL OF OPHTHALMOLOGY 86(11):1303-1305 Eter N; Spitznas M DMSO mimics inhibitory effect of thalidomide on choriocapillary endothelial cell proliferation in culture | 0 | 0 |
| 844 | 1 | 9 | 2144 2002 BRITISH JOURNAL OF OPHTHALMOLOGY 86(11):1315-1316 Shuttleworth GN; Cook SD; Ropner JE Vanishing corneal epithelial crystals following thalidomide induced resolution of myeloma related paraproteinaemia | 0 | 0 |
| 845 | 8 | 38 | 1895 2001 BRITISH JOURNAL OF PHARMACOLOGY 133(8):1414-1423 Lienenluke B; Stojanovic T; Fiebig T; Fayyazi A; Germann T; Hecker M Thalidomide impairment of trinitrobenzene sulphonic acid-induced colitis in the rat-role of endothelial cell-leukocyte interaction | 3 | 4 |
| 846 | 0 | 2 | 2145 2002 BRITISH JOURNAL OF PHARMACOLOGY 137 Paxton JW; Kestell P; Ding Q; Ching LM; Zhou S; Palmer BD; Baguley BC Preliminary investigations into the pharmacokinetic interaction between cyclophosphamide and thalidomide in the mouse | 0 | 0 |
| 847 | 1 | 19 | 6 1960 BRITISH JOURNAL OF PHARMACOLOGY AND CHEMOTHERAPY 15(1):111-116 SOMERS GF PHARMACOLOGICAL PROPERTIES OF THALIDOMIDE (ALPHA-PHTHALIMIDO GLUTARIMIDE) - NEW SEDATIVE HYPNOTIC DRUG | 52 | 71 |
| 848 | 1 | 7 | 316 1965 BRITISH JOURNAL OF PHARMACOLOGY AND CHEMOTHERAPY 25(2):324-& SCHUMACHER H; SMITH RL; WILLIAMS RT METABOLISM OF THALIDOMIDE - SPONTANEOUS HYDROLYSIS OF THALIDOMIDE IN SOLUTION | 89 | 98 |
| 849 | 4 | 13 | 317 1965 BRITISH JOURNAL OF PHARMACOLOGY AND CHEMOTHERAPY 25(2):338-& SCHUMACHER H; SMITH RL; WILLIAMS RT METABOLISM OF THALIDOMIDE - FATE OF THALIDOMIDE AND SOME OF ITS HYDROLYSIS PRODUCTS IN VARIOUS SPECIES | 59 | 72 |
| 850 | 7 | 21 | 318 1965 BRITISH JOURNAL OF PHARMACOLOGY AND CHEMOTHERAPY 25(2):352-& FABRO S; SCHUMACHER H; SMITH RL; STAGG RBL; WILLIAMS RT METABOLISM OF THALIDOMIDE-SOME BIOLOGICAL EFFECTS OF THALIDOMIDE AND ITS METABOLITES | 26 | 31 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 851 | 0 | 0 | 319 1965 BRITISH JOURNAL OF PREVENTIVE & SOCIAL MEDICINE 19(2):94-& OTTERLAN.A EFFECT OF THALIDOMIDE WARNING ON MEDICINE PRESCRIBED FOR PREGNANT WOMEN - ANALYSIS OF FREE MEDICINES DELIVERED TO EXPECTANT MOTHERS IN VASTERBOTTEN COUNTY OF SWEDEN DURING 1961 AND 1962 | 0 | 0 |
| 852 | 0 | 1 | 591 1974 BRITISH JOURNAL OF PSYCHIATRY 124(MAY):498-499 LADER M THALIDOMIDE AND POWER OF DRUG COMPANIES - SJOSTROM,H AND NILSSON,R | 0 | 0 |
| 853 | 5 | 8 | 54 1962 BRITISH JOURNAL OF RADIOLOGY 35(418):687-691 GRAINGER RG; MORRIS AH; WARD P PHOCOMELIC DEFORMITY AND MATERNAL THALIDOMIDE ADMINISTRATION - A REPORT OF 4 CASES | 1 | 2 |
| 854 | 1 | 1 | 881 1985 BRITISH JOURNAL OF RHEUMATOLOGY 24(1):95-96 JENKINS JS; POWELL RJ; MAURICE P; LITTLEWOOD S; ALLEN BR THALIDOMIDE IN THE TREATMENT OF OROGENITAL ULCERATION | 0 | 0 |
| 855 | 19 | 23 | 1319 1997 BRITISH JOURNAL OF RHEUMATOLOGY 36(3):353-359 Stevens RJ; Andujar C; Edwards CJ; Ames PRJ; Barwick AR; Khamashta MA; Hughes GRV Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: Experience in sixteen consecutive patients | 36 | 49 |
| 856 | 0 | 1 | 619 1976 BRITISH JOURNAL OF SOCIAL WORK 6(3):410-411 SAINSBURY S THALIDOMIDE - MY FIGHT - MASON,D | 0 | 0 |
| 857 | 5 | 16 | 642 1977 BRITISH JOURNAL OF SURGERY 64(3):203-204 SHAND JEG; BREMNER DN AGENESIS OF VERMIFORM APPENDIX IN A THALIDOMIDE CHILD | 4 | 9 |
| 858 | 0 | 0 | 2 1959 BRITISH MEDICAL JOURNAL 2(OCT3):635-635 DESOUZA LP THALIDOMIDE | 2 | 3 |
| 859 | 0 | 1 | 3 1959 BRITISH MEDICAL JOURNAL 2(NOV21):1099-1099 RUDD TN THALIDOMIDE | 0 | 1 |
| 860 | 0 | 1 | 4 1959 BRITISH MEDICAL JOURNAL 2(OCT31):888-888 NYAZAI AKK THALIDOMIDE | 1 | 2 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 861 | 0 | 0 | 7 1960 BRITISH MEDICAL JOURNAL 2(DEC31):1954-1954 FLORENCE AL IS THALIDOMIDE TO BLAME | 43 | 51 |
| 862 | 0 | 0 | 13 1961 BRITISH MEDICAL JOURNAL 1(521):130-& BURLEY DM IS THALIDOMIDE TO BLAME | 0 | 0 |
| 863 | 0 | 0 | 14 1961 BRITISH MEDICAL JOURNAL 1(521):130-& BURLEY D IS THALIDOMIDE TO BLAME | 17 | 19 |
| 864 | 0 | 0 | 15 1961 BRITISH MEDICAL JOURNAL 1(522):291-& KUENSSBERG EV; STANTON JB; SIMPSON JA IS THALIDOMIDE TO BLAME | 10 | 13 |
| 865 | 0 | 0 | 16 1961 BRITISH MEDICAL JOURNAL 1(522):829-& SHAFAR J IS THALIDOMIDE TO BLAME | 2 | 3 |
| 866 | 0 | 1 | 17 1961 BRITISH MEDICAL JOURNAL 2(NOV11):1287-& SIMPSON JA NEUROPATHY AFTER THALIDOMIDE (DISTAVAL) | 4 | 7 |
| 867 | 0 | 0 | 18 1961 BRITISH MEDICAL JOURNAL 2(524):125-& [Anon] PURPURA ASSOCIATED WITH THALIDOMIDE | 0 | 0 |
| 868 | 0 | 0 | 19 1961 BRITISH MEDICAL JOURNAL 2(525):660-& LONGSTAFF JHL PURPURA ASSOCIATED WITH THALIDOMIDE | 0 | 0 |
| 869 | 3 | 9 | 20 1961 BRITISH MEDICAL JOURNAL 2(525):855-& FULLERTON PM; KREMER M NEUROPATHY AFTER INTAKE OF THALIDOMIDE (DISTAVAL) | 61 | 87 |
| 870 | 3 | 5 | 21 1961 BRITISH MEDICAL JOURNAL 2(525):876-& [Anon] THALIDOMIDE NEUROPATHY | 1 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 871 | 0 | 0 | 22 1961 BRITISH MEDICAL JOURNAL 2(525):1025-& CHEVENS LCF NEUROPATHY AFTER THALIDOMIDE | 2 | 3 |
| 872 | 0 | 0 | 23 1961 BRITISH MEDICAL JOURNAL 2(525):1084-& HOWE P NEUROPATHY AFTER THALIDOMIDE (DISTAVAL) | 5 | 6 |
| 873 | 0 | 0 | 24 1961 BRITISH MEDICAL JOURNAL 2(525):1084-& HEATHFIELD K G NEUROPATHY AFTER THALIDOMIDE (DISTAVAL) | 0 | 5 |
| 874 | 0 | 0 | 25 1961 BRITISH MEDICAL JOURNAL 2(526):1151-& POWELLTUCK GA NEUROPATHY AFTER THALIDOMIDE DISTAVAL | 4 | 5 |
| 875 | 0 | 0 | 26 1961 BRITISH MEDICAL JOURNAL 2(526):1223-& STEVENSON JS NEUROPATHY AFTER THALIDOMIDE (DISTAVAL) | 0 | 4 |
| 876 | 0 | 0 | 27 1961 BRITISH MEDICAL JOURNAL 2(526):1223-& MEADE BW; ROSALKI SB NEUROPATHY AFTER THALIDOMIDE (DISTAVAL) | 4 | 8 |
| 877 | 0 | 0 | 28 1961 BRITISH MEDICAL JOURNAL 2(526):1223-& CAHILL PK NEUROPATHY AFTER THALIDOMIDE (DISTAVAL) | 2 | 4 |
| 878 | 0 | 0 | 29 1961 BRITISH MEDICAL JOURNAL 2(526):1286-& JEWESBURY ECO; GREENHALGH RN; SIMPSON JA; BURLEY D; RUDD TN NEUROPATHY AFTER THALIDOMIDE (DISTAVAL) | 2 | 2 |
| 879 | 0 | 0 | 30 1961 BRITISH MEDICAL JOURNAL 2(526):1359-& MAGRATH D NEUROPATHY AFTER THALIDOMIDE (DISTAVAL) | 2 | 2 |
| 880 | 0 | 0 | 31 1961 BRITISH MEDICAL JOURNAL 2(526):1359-& BROWN JA NEUROPATHY AFTER THALIDOMIDE (DISTAVAL) | 2 | 2 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 881 | 0 | 0 | 32 1961 BRITISH MEDICAL JOURNAL 2(526):1435-& HAYMAN DJ NEUROPATHY AFTER THALIDOMIDE (DISTAVAL) | 1 | 2 |
| 882 | 0 | 0 | 33 1961 BRITISH MEDICAL JOURNAL 2(526):1498-& SWIFT EF NEUROPATHY AFTER THALIDOMIDE (DISTAVAL) | 1 | 1 |
| 883 | 0 | 0 | 34 1961 BRITISH MEDICAL JOURNAL 2(526):1498-& KREMER M; FULLERTON PM NEUROPATHY AFTER THALIDOMIDE (DISTAVAL) | 2 | 3 |
| 884 | 0 | 0 | 35 1961 BRITISH MEDICAL JOURNAL 2(526):1498-& PIRRIE I NEUROPATHY AFTER THALIDOMIDE (DISTAVAL) | 2 | 2 |
| 885 | 0 | 0 | 36 1961 BRITISH MEDICAL JOURNAL 2(526):1499-& HAYMAN DJ WITHDRAWAL OF THALIDOMIDE (DISTAVAL) | 3 | 6 |
| 886 | 0 | 0 | 37 1961 BRITISH MEDICAL JOURNAL 2(526):1570-& HOWE P NEUROPATHY AFTER THALIDOMIDE (DISTAVAL) | 6 | 7 |
| 887 | 0 | 1 | 38 1961 BRITISH MEDICAL JOURNAL 2(526):1570-& BARTHOLOMAY A NEUROPATHY AFTER THALIDOMIDE (DISTAVAL) | 0 | 9 |
| 888 | 0 | 0 | 39 1961 BRITISH MEDICAL JOURNAL 2(526):1644-& GOSLING PH WITHDRAWAL OF THALIDOMIDE (DISTAVAL) | 1 | 1 |
| 889 | 0 | 0 | 40 1961 BRITISH MEDICAL JOURNAL 2(526):1716-& HAYMAN DJ WITHDRAWAL OF THALIDOMIDE (DISTAVAL) | 1 | 1 |
| 890 | 1 | 2 | 55 1962 BRITISH MEDICAL JOURNAL (5270):55-& SIMPSON JA MYXOEDEMA AFTER THALIDOMIDE (DISTAVAL) | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 891 | 4 | 6 | 56 1962 BRITISH MEDICAL JOURNAL (5276):477-& WILLMAN A; DUMOULIN JG THALIDOMIDE (DISTAVAL) AND FOETAL ABNORMALITIES | 0 | 0 |
| 892 | 1 | 3 | 57 1962 BRITISH MEDICAL JOURNAL (5276):477-& LILLICRAP DA MYXOEDEMA AFTER THALIDOMIDE (DISTAVAL) | 0 | 0 |
| 893 | 0 | 0 | 58 1962 BRITISH MEDICAL JOURNAL (5280):792-& ROBERTSON WF THALIDOMIDE (DISTAVAL) AND VITAMIN-B DEFICIENCY | 0 | 0 |
| 894 | 1 | 1 | 59 1962 BRITISH MEDICAL JOURNAL (5280):792-& MORGAN BC THALIDOMIDE (DISTAVAL) AND FOETAL ABNORMALITIES | 1 | 2 |
| 895 | 0 | 0 | 60 1962 BRITISH MEDICAL JOURNAL (5283):1025-& [Anon] PERIPHERAL NEURITIS DUE TO THALIDOMIDE | 0 | 0 |
| 896 | 2 | 4 | 61 1962 BRITISH MEDICAL JOURNAL (5290):1469-& [Anon] THALIDOMIDE (DISTAVAL) IN MEDICINE CUPBOARDS | 0 | 0 |
| 897 | 1 | 2 | 62 1962 BRITISH MEDICAL JOURNAL (5294):1758-& WIGGLESWORTH R; WRIGHT GB THALIDOMIDE (DISTAVAL) AND FOETAL ABNORMALITIES | 0 | 0 |
| 898 | 0 | 0 | 63 1962 BRITISH MEDICAL JOURNAL (5298):175-& [Anon] PROSTHESES FOR INFANTS WITH DEFORMITIES CAUSED BY THALIDOMIDE | 0 | 0 |
| 899 | 0 | 0 | 64 1962 BRITISH MEDICAL JOURNAL (5299):236-& WOOLLAM DHM THALIDOMIDE DISASTER CONSIDERED AS AN EXPERIMENT IN MAMMALIAN TERATOLOGY | 0 | 0 |
| 900 | 0 | 0 | 65 1962 BRITISH MEDICAL JOURNAL (5299):261-& WHITEFRA.A; RATTENBURY G HELP FOR THALIDOMIDE BABIES | 0 | 0 |
Page 3: 1 2 3 4 5 6 7 8 9
Generated by: HistCite(Vlad).
Version: 2004.09.22